Vaisala Oyj tilinpäätöstiedote tammi–joulukuu 2019
Vaisala Oyj Tilinpäätöstiedote 12.2.2020 klo 14.00 Vaisala Oyj tilinpäätöstiedote tammi–joulukuu 2019
Day: February 12, 2020
Cowen Announces Fourth Quarter and Full Year 2019 Financial Results
Written by Customer Service on . Posted in Public Companies.
Record Revenues for Fourth Quarter and Full Year 2019Reports 4Q19 GAAP EPS of $0.11 and Economic Operating EPS of $0.58Establishes Quarterly Cash Dividend of $0.04 Per Common ShareNEW YORK, Feb. 12, 2020 (GLOBE NEWSWIRE) — Cowen Inc. (NASDAQ: COWN) (“Cowen” or “the Company”) today announced its operating results for the fourth quarter and full year ended December 31, 2019.Jeffrey M. Solomon, Chairman and Chief Executive Officer of Cowen, said, “In 2019, we made considerable progress by simplifying our business, diversifying revenues and ensuring that we can achieve consistent profitability for the long run. The investments we made – the Quarton acquisition, the hiring of new teams in banking and markets, and improvements to our technology and infrastructure – all position us well as we look ahead to 2020. We are...
Calibre Mining Q4 2019 Conference Call and Webcast on February 19, 2020
Written by Customer Service on . Posted in Public Companies.
VANCOUVER, British Columbia, Feb. 12, 2020 (GLOBE NEWSWIRE) — Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) (the “Company” or “Calibre”) will release its fourth quarter financial and operating results on Tuesday, February 18, 2020 after the market close. Management will host a conference call and webcast to discuss the 2019 results and the outlook for 2020 on February 19, 2020 at 10:00 a.m. (ET). Conference call and webcast details as follows:Presentation slides which accompany the conference call can be accessed at www.calibremining.com under Investors and Presentations section of the Calibre website (link here).About Calibre Mining Corp.Calibre Mining is a Canadian-listed gold mining and exploration company with two 100%-owned operating gold mines in Nicaragua. The Company is focused on sustainable operating performance and a...
Green Thumb Industries (GTI) To Hold Fourth Quarter and Full Year 2019 Earnings Conference Call on March 26, 2020
Written by Customer Service on . Posted in Public Companies.
CHICAGO and VANCOUVER, British Columbia, Feb. 12, 2020 (GLOBE NEWSWIRE) — Green Thumb Industries Inc. (GTI) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise™ and Essence retail stores, today announced that it will hold a conference call on Thursday, March 26, 2020, at 5:00 pm ET following the release of its fourth quarter and full year 2019 financial results after market close.The earnings conference call may be accessed by dialing 877-273-8145 (Toll-Free) or 647-689-5400 (International) with conference ID: 6538599. A live audio webcast of the call will also be available on the Investor Relations section of GTI’s website at https://www.gtigrows.com/investors and will be archived for replay.About Green Thumb Industries:Green Thumb Industries (GTI), a national cannabis consumer...
Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA
Written by Customer Service on . Posted in Public Companies.
Orphan Drug Designation Granted for Treatment of Gaucher Disease Rare Pediatric Disease Designation Granted for Treatment ofNeuronopathic Gaucher DiseaseNEW YORK, Feb. 12, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the Company’s investigational gene therapy, PR001, for the treatment of patients with Gaucher disease. The Company also announced that the FDA has granted Rare Pediatric Disease Designation for PR001 for the treatment of neuronopathic Gaucher disease (nGD), the most severe form of the condition.“We are pleased to receive these important...
IPG Announces Full Year and Fourth Quarter 2019 Results
Written by Customer Service on . Posted in Public Companies.
New York, Feb. 12, 2020 (GLOBE NEWSWIRE) —Q4 2019 net revenue was $2.43 billion, with organic net revenue growth of 2.9%, comprised of 2.1% in the U.S. and 4.1% in international marketsFY19 net revenue grew 7.4%, with organic net revenue growth of 3.3%FY19 net income was $656.0 million compared to $618.9 million in 2018, and adjusted EBITA was $1.20 billion compared with $1.08 billion in 2018Adjusted EBITA margin expanded to 14.0% for FY19, an increase of 50 basis points from comparable FY18FY19 diluted EPS was $1.68 and was $1.93 as adjustedBoard approves 9% increase in quarterly dividendSummaryRevenueFourth quarter 2019 net revenue was $2.43 billion, compared to $2.41 billion in 2018, with an organic net revenue increase of 2.9% compared to the prior-year period. This was comprised of an organic net revenue increase of 2.1% in the...
Nilörngruppen AB: Year End Report Q4-2019
Written by Customer Service on . Posted in Public Companies.
Period October – December·Order bookings increased by 3 percent to MSEK 188 (182).·Revenue decreased by 8 percent to MSEK 172 (186).·Operating profit amounted to MSEK 11.6 (25.4).·Profit for the period amounted to MSEK 7.1 (26.3).·Earnings per share amounted to SEK 0.62 (2.30).Period January – December·Order bookings increased by 1.5 percent and amounted to MSEK 749 (738).·Revenue increased by 0.4 percent to MSEK 715 (712).·Revenue adjusted for currency effects amounted to MSEK 682 (712), i.e. an underlying organic decrease of 4 percent.·Operating profit amounted to MSEK 66.2 (85.2).·Profit for the period amounted to MSEK 47.2 (70.7).·Earnings per share amounted to SEK 4.14 (6.20).Significant events during the quarter·Lower revenue from a number of major customers, especially in Britain.·The fourth quarter of the year before...
Nilörngruppen AB: Bokslutskommuniké 2019
Written by Customer Service on . Posted in Public Companies.
Period October – December·Order bookings increased by 3 percent to MSEK 188 (182).·Revenue decreased by 8 percent to MSEK 172 (186).·Operating profit amounted to MSEK 11.6 (25.4).·Profit for the period amounted to MSEK 7.1 (26.3).·Earnings per share amounted to SEK 0.62 (2.30).Period January – December·Order bookings increased by 1.5 percent and amounted to MSEK 749 (738).·Revenue increased by 0.4 percent to MSEK 715 (712).·Revenue adjusted for currency effects amounted to MSEK 682 (712), i.e. an underlying organic decrease of 4 percent.·Operating profit amounted to MSEK 66.2 (85.2).·Profit for the period amounted to MSEK 47.2 (70.7).·Earnings per share amounted to SEK 4.14 (6.20).Significant events during the quarter·Lower revenue from a number of major customers, especially in Britain.·The fourth quarter of the year before...
Correction: HSBC BANK PLC – Form 8.5 (EPT/RI) – NMC Health plc
Written by Customer Service on . Posted in Mergers And Acquisitions.
Amendment to Section 2(a)FORM 8.5 (EPT/RI)PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITYRule 8.5 of the Takeover Code (the “Code”)1. KEY INFORMATION2. DEALINGS BY THE EXEMPT PRINCIPAL TRADERWhere there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.The currency of all prices and other monetary amounts should be stated.(a) Purchases and sales(b) Cash-settled derivative transactions(c) Stock-settled derivative transactions (including options)(i) Writing, selling, purchasing or varying(ii) Exercise(d) Other dealings (including subscribing...
Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference
Written by Customer Service on . Posted in Public Companies.
SALT LAKE CITY, Feb. 12, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that R. Bryan Riggsbee, president and CEO, is scheduled to present at the SVB Leerink Global Healthcare Conference at 10:30 a.m. EST on February 25, 2020 in New York City.The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.About Myriad GeneticsMyriad Genetics, Inc., is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose...
